NeurAxis (NRXS): Analyzing the +66% Upside Potential to the $11 Target

Key Takeaways

• The central target of $11 is the arithmetic mean of two verified analyst price targets, which range from $9 to $13.
• At a recent price near $6.61, reaching $11 would require an upside of about 66%, a very large move for a small-cap stock.
• Craig-Hallum (analyst Chase Knickerbocker) holds a Buy rating and a $13 target, while a second analyst carries a $9 target.
• The strongest support comes from accelerating revenue growth, expanding payer coverage, and a new Category I CPT reimbursement code.
• The biggest risks are a thin cash balance, ongoing going-concern language, persistent losses, and the wide gap to the stock's prior high.

Analyst Price Targets and Consensus View

Coverage of NRXS remains limited, as is typical for a company of this size. Two current analyst price targets stand out. Craig-Hallum’s Chase Knickerbocker kept a Buy rating and lifted his target from $8 to $13 in March 2026, while another analyst maintains a $9 target. This creates a low-to-high range of $9 to $13, with the mean landing at $11—the central figure used here.

With only two targets available, the average should be viewed with caution rather than as a broad Wall Street consensus. The spread between $9 and $13 highlights real differences in views on how quickly reimbursement-driven growth can lead to financial stability. Neither number represents a guarantee.

Current Market Position and Path Toward the Target

Trading near $6.61, the stock would need to rise about 66% to hit $11. That represents a substantial move. Notably, the $11 target sits above the 52-week high of roughly $9.33, so shares would have to set new highs rather than simply recover prior ground. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to monitor recent technical shifts.

Reaching the target would likely hinge on continued revenue acceleration, further payer coverage gains, and signs that the company is approaching cash-flow breakeven. In the quarter reported in early November 2026, revenue climbed roughly 150% year over year to about $2.03 million, though it fell just short of estimates and the loss per share widened to $0.52, exceeding expectations.

What Could Support a Move Toward the Target

• Accelerating growth: Revenue growth has quickened for several consecutive quarters, supported by rising device volumes and a higher average selling price.
• Reimbursement tailwinds: A Category I CPT code took effect, and two large national payers reportedly added tens of millions of covered lives, lifting total covered lives toward roughly 147 million.
• Strong gross margins: Gross margin expanded to about 86.6%, reflecting a shift toward full-reimbursement sales.
• Expanding adoption: Ordering accounts and revenue per account have trended higher, suggesting growing clinician uptake.

What Could Prevent the Target From Being Reached

• Balance-sheet pressure: Cash declined in the quarter, and the company has reactivated its at-the-market facility, indicating a need for additional capital.
• Ongoing losses: The business remains unprofitable, with significant general and administrative expenses and a going-concern disclosure still in place.
• Slower reimbursement roll-out: Medicaid fee-schedule implementation and prior-authorization hurdles could delay revenue recognition.
• Small-cap volatility: With a market capitalization around $80 million and limited float, the shares can move sharply on modest news or fund flows.

Technical Levels and Market Structure

On a technical basis, the 52-week low near $2.21 and the 52-week high near $9.33 frame a wide trading range. The 200-day moving average sits near $6.71, close to the current price, suggesting the longer-term trend remains contested. The $9.33 prior high is a meaningful resistance level, and psychological levels around $9 and $10 would need to be cleared before the $11 target becomes relevant.

Time Horizon and What Investors Should Monitor

Analyst price targets generally reflect a research horizon of roughly 12 months, though no specific horizon was disclosed for these two targets. Investors should watch quarterly revenue growth and gross margin, any updates on payer coverage and the Medicaid fee schedule, cash burn and financing activity, and whether management provides clearer guidance on the path to profitability. Revisions to the two existing analyst targets would also be significant given how little coverage exists.

AI Daily Buy/Sell Signals

In my own analysis, I frequently rely on Tickeron’s AI Daily Buy/Sell Signals to stay on top of shifting conditions. The platform applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals drawn from technical behavior and market dynamics. This helps surface opportunities and track trends more efficiently than manual reviews alone.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.

Notable companies

Industry description

Market Cap

High and low price notable news

Volume